Thomas Sénard, from France, graduated with a MSc in Biotechnology and Proteomics from the University of Lille I, Sciences and Technologies (France), and a MSc in Biomolecular Science from Toho University (Japan), within the EDU-NEURO EU-JP programme. His GlySign PhD project is taking place at the Leiden University Medical Centre (LUMC) in Leiden, the Netherlands. A substantial part of the training will be carried out at Genos Ltd, (Zagreb, HR). His project is supervised by Dr. David Falck (LUMC) and by Dr. Maja Pučić Baković (Genos), and is entitled “Absolute LC-MS based quantitation of serum IgG Fc N-glycosylation for patient stratification in chronic inflammatory diseases”. His scientific interests are focused on glycomics, mass spectrometry-based proteomics and immunology.
Iwona Wójcik, from Poland, graduated with a Master’s degree in Biotechnology from the Faculty of Biochemistry, Biophysics and Biotechnology at Jagiellonian University in Krakow, Poland. During her studies and year-round internship at Malopolska Centre of Biotechnology her scientific work has contributed to understanding the secreted exoproteome fingerprints of highly-virulent and non-virulent strains of Staphylococcus aureus. Since May 2017, she is employed in Genos Ltd, Zagreb, Croatia. Her GlySign PhD project is focused on the glycosylation analysis of total and antigen-specific serum IgG for disease severity estimation in fetal/neonatal alloimmune thrombocytopenia patients and is supervised by Dr. Maja Pucic Bakovic (Genos Ltd., HR), Dr. David Falck and Prof. Manfred Wuhrer (both at LUMC, NL). Her scientific interests are focused on glycobiology, mass spectrometry-based proteomics, protein chemistry and biomarker discovery, verification and validation
Osmond Rebello, from India, graduated with M.Sc. in Biochemistry and Molecular Biology from Bremen University, Bremen (Germany). Next to his studies, he was working part-time as a technical assistant at the Nano-SIMS facility of the Max Planck Institute, Bremen (2014-2017). His GlySign PhD project is entitled ’Plated-based enzyme assays for IgG Fc analysis for patient stratification in auto- and alloimmune diseases’. His project takes place at Ludger Ltd (UK) under the supervision of Dr. Daniel Spencer. An extensive period of his PhD project will be spent at the Center of Proteomics and Metabolomics at the Leiden University Medical Center (LUMC) in Leiden (Leiden, NL) under the supervision of Dr. David Falck and Prof. Manfred Wuhrer. He will also spend a short period of time at Prozomix Ltd (United Kingdom). His scientific interests are protein Biochemistry, glycomics and proteomics, mass spectrometry, chromatography and structural biology.
Alan Moran, from Ireland, graduated in 2015 with a BSc in Genetics from University College Dublin. In 2016, he obtained a diploma in Biopharmaceutical Operations at the National Institute of Bioprocessing Research and Training (NIBRT) in Dublin before being employed there as an Analytical Scientist for a period of 9 months. In 2017, Alan joined GlySign under the supervision of Prof. Dr. Manfred Wuhrer, Guinevere Kammeijer (LUMC, NL), and Dr. Daniel Spencer (Ludger Ltd., UK). He will spend a significant proportion of his PhD at each institution where he will focus on the analysis of the glycosylation of prostate-specific antigen (PSA) in prostate cancer in order to improve patient stratification. For this purpose, Alan is exploring the usage of a variety of separation techniques (LC/CE) and the on-line coupling (ESI) to mass spectrometry (Q-TOF/FT-ICR), as well as the development and validation of a clinical assay. His scientific interests include the translation of proteomic and glycomic research to the clinics and industry.
Elham Memarian, from Iran, graduated in analytical chemistry from the faculty of chemistry at Shahid Beheshti University (Tehran, Iran). For her Master’s thesis she was working on the “Optimization of solid phase microextraction and electromembrane extraction techniques to measure certain pollutants and drugs”. During her studies, she was awarded medals and honorary diplomas from international and national competitions and expositions because of her inventions, such as a Silver Medal for an automatic painting device with re-absorption capability at the INVENTIKA 2010 International Trade show. In June 2017, she started her Glysign PhD project, conducting research at Genos Ltd., Zagreb, Croatia, and the Leiden University Medical Centre (LUMC) in Leiden, the Netherlands. Her supervisors at Genos are Dr. Maja Pučić Baković and Prof. Gordan Lauc, and at the LUMC Dr. Viktoria Dotz and Prof. Manfred Wuhrer. Elham’s research is geared towards the quantification of serum protein glycosylation for patient stratification in early-onset and other diabetes types.
Daniel Demus graduated in 2016 with an MSc in Biotechnology from the University of Life Sciences in Lublin, Poland. During his master studies he spent 12 months as an intern in the QA/QC department at Merck, Darmstadt, Germany. In 2017, Daniel started his PhD as an early stage researcher under the GlySign project under the supervision of Dr. Daniel Spencer (Ludger Ltd, UK), Prof. Manfred Wuhrer and Dr. Viktoria Dotz (LUMC, NL). His PhD project is focused on multi-platform high-throughput analysis of early-onset diabetes patient samples, using orthogonal LC-MS, MALDI and plate based enzymatic approaches. His main scientific interests include medical biotechnology and multiomics technologies.